Browse Penn-owned technologies available for licensing.
The Robertson group has developed a small molecule therapeutic for hematologic malignancies that inhibit a key cancer cell signaling pathway, causing cell death. This small molecule therapeutic has increased inhibitory action on cancer cells and decreased toxicity to healthy cells as compared to existing treatments. This results in a more specific mechanism of action that reduces the incidence of side effects such as nausea, fever, chills, and anorexia. The molecules are expected to be applicable to a broad range of hematologic malignancies.